Asset Details
Do you wish to reserve the book?
Proanthocyanidins inhibit CYP1B1 through mixed-type kinetics and stable binding in molecular dynamics simulations
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Proanthocyanidins inhibit CYP1B1 through mixed-type kinetics and stable binding in molecular dynamics simulations
Do you wish to request the book?
Proanthocyanidins inhibit CYP1B1 through mixed-type kinetics and stable binding in molecular dynamics simulations
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Proanthocyanidins inhibit CYP1B1 through mixed-type kinetics and stable binding in molecular dynamics simulations
2025
Overview
Cytochrome P450 1B1 (CYP1B1) is a heme-containing enzyme involved in procarcinogen activation and estrogen metabolism, contributing to tumor progression. This study investigates the inhibitory effects of proanthocyanidin (PA) on CYP1B1-catalyzed reactions and its underlying mechanisms. Enzyme kinetics revealed that PA exerts mixed-type inhibition with an IC₅₀ of 2.53 ± 0.01 μM. Molecular docking demonstrated that PA binds to key residues (Phe231, Gly329, Ala330, Asn228, Asn265) and the heme cofactor through hydrogen bonding and π–π stacking, interfering with substrate binding and electron transfer. Molecular dynamics simulations over 200 ns confirmed the stability of the PA-CYP1B1 complex. To validate the stability and inhibitory relevance of the simulation results, berberine, a known CYP1B1 inhibitor, was used as a positive control in parallel analyses. In silico ADMET prediction indicated high intestinal absorption and a favorable safety profile, with no significant CYP inhibition or mutagenicity. However, low membrane permeability and multiple drug-likeness violations suggest limited oral bioavailability. These findings support the potential of PA as a natural CYP1B1 inhibitor for cancer prevention and treatment. Further structural optimization or formulation strategies may enhance its pharmacokinetic properties and clinical applicability.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ ADMET
/ CYP1B1
/ Cytochrome P-450 CYP1B1 - antagonists & inhibitors
/ Cytochrome P-450 CYP1B1 - chemistry
/ Cytochrome P-450 CYP1B1 - metabolism
/ Enzymes
/ Heme
/ Humanities and Social Sciences
/ Humans
/ Kinetics
/ Ligands
/ Molecular Docking Simulation
/ Molecular Dynamics Simulation
/ Proanthocyanidins - chemistry
/ Proanthocyanidins - metabolism
/ Proanthocyanidins - pharmacology
/ Proteins
/ Science
/ Tumors
